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Abstract 
Type 2 diabetes (T2D) has become a major problem around the world. Current 
research has linked a high dietary fibre (DF)- intake with a number of health bene-
fits and possible prevention of T2D. One proposed mechanism is via short chain 
fatty acids (SCFA), which are produced from fermentation of DF in the colon by 
the microflora. A high DF intake will cause higher concentration of SCFA in the 
blood. In order to investigate the role of T2D it is of importance to have an easy, 
robust fast and accurate method for determine the concentration of SCFA in a small 
volume serum and plasma from fasted individuals. In the protocol used the sample 
preparation relies on the ability for proteins to form a precipitate with phosphoric 
acid and extraction of supernatant in organic solvent. The concentration is measured 
by gas chromatography-mass spectrometry (GC-MS). The aim of the present study 
was brief to further develop and validate an existing rapid GC-MS based method to 
determine the concentration of SCFA in serum from human subjects, including an 
extension of an existing protocol for SCFA analysis in 400 µl to the reduced vol-
ume of 200 µl was evaluated, the agreement of method, using plasma or serum for 
determination of SCFA in a small population if individuals (n=30) was evaluated.  
The measured SCFAs were acetate, butyrate, iso-butyrate, propionate, valerate, iso-
valerate and caproate. The method developed could analyse 200 µl serum and 
plasma with acceptable precision. The accuracy was tested with spiking acetate at 
106.6, 53.3 and 26.7 µM and the other SCFA at 10.7, 5.3 and 2.7 µM. The recovery 
were between 80.1-107.7 %. The fasting concentration of acetate was 86.0-313.3 
µM, 19.4-28.5 µM for propionate, 2.6-4.7 µM for iso-butyrate, 9.2-29.1 µM for 
butyrate, 11.2-44.4 µM for iso-valerate, 0.2-0.4 µM for valerate and 1.4-9.7 µM for 
caproate, of the 30 subjects. It was a good agreement between serum and plasma 
concentration for butyrate. For propionate, valerate, acetate, iso-butyrate, iso-
valerate and caproate there were a significant difference.  
Keywords: Short Chain Fatty Acids, Type 2 Diabetes, GC-MS, Dietary Fibre, Se-
rum, Plasma 
Sammanfattning 
Typ 2 diabetes har blivit ett omfattande problem världen runt. Rådande forskning 
har sett samband mellan en diet rik på kostfiber och minskad ohälsa samt en möjlig 
förebyggande effekt mot att utveckla diabetes typ 2. En föreslagen mekanism är via 
kortkedjiga fettsyror. Ett högt intag av kostfiber resulterar i en högre koncentration 
av kortkedjiga fettsyror i blodet. För att undersöka typ 2 diabetes roll är det viktigt 
att ha en enkel, robust och noggrann metod vid mätning av koncentrationen kort-
kedjiga fettsyror i en liten volym i serum och plasma. Den använda metoden är 
baserad på proteiners förmåga att bilda en fällning med fosforsyra och sedan ex-
traktion med en organisk syra. Koncentrationerna av fettysorna uppmätts med 
gaskromatografi- masspektrometri (GC-MS). Syftet med denna studie var kortfattat 
att vidareutveckla och validera en befintlig GC-MS baserad metod för att noggrant 
bestämma koncentrationen av kortkedjiga fettsyror i humant serum, inklusive att 
utveckla metoden för 400 µl och till reducerad volymen (200 µl) men även att ut-
värdera sambandet mellan koncentration av kortkedjiga fettsyror i serum och 
plasma i en liten population (n=30). De kortkedjiga fettsyror som analyserades var 
acetat, butyrat, iso-butyrat, propionat, valerat, iso-valerat och kaproat.  Den utveck-
lade metoden kunde analysera 200 µl serum och plasma med god precision. Nog-
grannheten mättes genom att addera lösning med 106,6, 53,3 och 26,7 µM acetat 
och de andra fettsyrorna 10,7, 5,3 och 2,7 µM, utbytet låg mellan 80,1-107.7%. 
Koncentrationerna var vid fasta för de 30 individerna mellan 86,0-313,3 µM för 
acetat, 19.4-28.5µM för propionat, 2.6-4.7µM för iso-butyrat, 9.2-29.1µM för buty-
rat, 11.2-44.4µM för iso-valerat, 0.2-0.4µM för valerat och 1.4-9.7µM for kaproate. 
Ett tydligt samband mellan butyrat koncentrationen serum och plasma uppvisades. 
För resterande kortkedjiga fettsyrorna var där en signifikant skillnad.  
Nyckelord: Kortkedjiga fettsyror, typ 2 diabetes, GC-MS, Kostfiber, Serum, 
Plasma 
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Abbreviations 
 
ACE Acetate 
BUT Butyrate 
CARP Caproate 
CV Coefficient of variation 
DF Dietary Fibre 
FFAR2 Free fatty acid receptor 2 
FFAR3 Free fatty acid receptor 3 
GC-MS Gas Chromatography- Mass Spectrometry 
ISO-BUT Iso-Butyrate 
ISO-VAL Iso-Valerate 
OGTT Oral Glucose Tolerance Test 
PRO Propionate 
SCFA   Short Chain Fatty Acids 
SD Standard deviation 
T2D Type 2 Diabetes 
VAL Valerate 
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1 Introduction 
1.1 Health and Dietary Fibre  
Lifestyle diseases such as metabolic syndrome (Kaur, 2014), obesity and type 2 
diabetes (T2D) are currently increasing worldwide (Wilde et al. 2004). A more 
sedentary lifestyle together with a higher energy intake is one of the reasons, but 
diet is also considered to be an important modifiable risk. Through their associa-
tion with health benefits, an increase in dietary fibre (DF)-intake has been dis-
cussed as one way to prevent and treat lifestyle diseases (Mudgil & Barak 2013). 
Treating mice with β-glucan have for example showed an improved glucose toler-
ance, decrease in insulin resistance and hyperinsulinemia, which all are risk factors 
of the metabolic syndrome (Choi et al. 2010). Similar results have been displayed 
through dietary interventions in humans with muffin high in β-glucan and resistant 
starch (Behall et al. 2006). β-Glucan is one of few food constituents that are ex-
cepted to carry a health claim because of its maintenance ability of blood lipid 
levels (EG 432/2012). Moreover, giving T2D patients psyllium, consisting of high 
amounts of the DF mucilage (Sangeethapriya & Siddhuraju 2014), was shown to 
result in decreased glucose absorption and reduction of total and cholesterol LDL 
(Sierra et al. 2002). A high fibre diet, particularly insoluble fibre, also gives an 
increase of faecal bulk and decrease in transit time, which promotes a normal laxa-
tion (Dahl et al. 2005). 
 
The DF definition has widely been discussed since it is not only based on chemical 
structure. The concept also includes a physical aspect, where the main physical 
function includes bulking, viscosity, fermentability and non-digestibility in the 
small intestine (Mudgil & Barak 2013).  Codex Alimentarius have tried to evaluate 
the DF definition and have proposed a definition in 2009; it requires a certain 
structure, non-digestibility and physiological health benefits, among others, for a 
food constituent to be defined as DF (Codex 2009). 
 
DF exists in largest amounts in cereals, legumes, fruit and vegetables (Bartoli et 
al. 2007). They are the indigestible part of carbohydrates and include cellulose, 
hemicelluloses, pectin’s, hydrocolloids, β-glucans, gum, mucilages, lignin, α-
5 
 
galactosides, resistant starch and non-digestible oligosaccharides such as inulin 
(Mudgil & Barak 2013).   
 
DF can be divided into fermentable and non-fermentable where pectin, gums, mu-
cilages (Bartoli et al. 2007) and β-glucan are fermentable (Schroeder et al. 2013). 
The solubility of DF differs depending on structure. Oats, fruits, vegetables and 
pulses are rich in more soluble DFs (Mudgil & Barak 2013) such as β-glucans, 
some hemicelluloses, pectin, gums and mucilage’s (Jiménez-Escrig & Sánchez-
Muniz 2000) while less- or non-soluble DF often exists in the skin of fruit and 
vegetables (Mudgil & Barak 2013), examples are celluloses, lignin, arabinoxylan, 
some hemicellulose and resistant starch (Jiménez-Escrig & Sánchez-Muniz 2000). 
 
1.2 Dietary Fibre Degradation and SCFA 
Since adequate enzymes are lacking from the human endogenous metabolism, DF 
are resistant to human endogenous digestive enzymes, and consequently, cannot 
be absorbed in the small intestine. They can, however, influence absorption and 
digestion of nutrients indirectly, by affecting the accessibility, gastric emptying, 
digestion and nutrient absorption kinetics and thereby affect the levels of blood 
glucose, insulin, blood lipids, cholesterol and microflora in the gastrointestinal 
tract through other mechanisms (Den Besten et al. 2013).  
Fermentable DFs are fermented by gut microbial enzymes primarily in the upper 
colon. The fermentability relies on structure bonds within the fibre molecules and 
fibre solubility, where soluble DFs are more easily fermented (Mudgil & Barak, 
2013). A wide range of metabolites are produced from this microbial fermentation, 
such as carbon dioxide and methane, but also a high concentration of short chain 
fatty acids (SCFA) (Canfora et al. 2015). Although digestible carbohydrates and 
DF are the main substrates for fermentation, indigestible proteins, resistant starch 
and other substrates can also be microbially fermented in the colon (Soldavini & 
Kaunitz 2013).  SCFA are defined as volatile 1-6 carbon fatty acids that have a 
straight or branched conformation (Rios-Covián et al. 2016), where straight 
SCFAs are mainly derived from carbohydrates and branched SCFAs from proteins 
(Soldavini & Kaunitz 2013).  
 
Approximately 90% of the SCFA formed are absorbed in the colon and transport-
ed through the hepatic vein to the liver (den Besten et al. 2013; Soldavini & 
Kaunitz 2013) and the residual amount is secreted through the faeces (Canfora et 
al. 2015). Acetate, butyrate and propionate are the three most common SCFA 
(Figure 1) and together constitute 90-95% of the SCFAs in the colon. Other 
SCFAs, iso-butyrate, valerate, iso-valerate and caproat, are present in considerable 
lower concentrations (Topping & Clifton 2001). 
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Figure 1. The three most abundant SCFA. Acetate, Propionate and Butyrate. 
Together all SCFA constitute of 5-10% of the human energy requirement (Sol-
davini & Kaunitz, 2013) and general effect in the colon include the facilitation of 
water and electrolyte absorption (Rios-Covián et al. 2016). The most abundant 
SCFA in the gastrointestinal tract is acetate. It reaches circulation and can be used 
as energy by the host or acts as substrate for hepatic lipogenesis and cholesterol 
biosynthesis (Brüssow & Parkinson 2014). Acetate can protect the host by improv-
ing epithelial cells and intestinal defence (Fukuda et al. 2011). Propionate acts as 
substrate in the hepatic gluconeogenesis and is involved in the cholesterol produc-
tion (Brüssow & Parkinson 2014). Most of the butyrate is metabolized by the en-
terocytes in the colon and is used locally as energy source. This stimulates cell 
renewal, which improves the mucin production and the mucus barrier. Only small 
amounts reach the blood circulation and contribute as energy to the host (Pryde et 
al. 2002). Butyrate-producing bacteria are also believed to affect the blood glucose 
regulation and lipid metabolism (Puddu et al. 2014).  
 
A high intake of DF causes higher concentration of SCFA in the gastrointestinal 
tract and in the blood (De Filippo et al. 2010). The rate of production of the indi-
vidual SCFA is dependent on substrate and thus related by the diet, whereas the 
distribution of SCFAs produced, i.e. the SCFA profile, is determined by microbio-
ta composition, molecular weight of the substrate and the amount of undigested 
matter that reaches the colon (den Besten et al. 2013; De Filippo et al. 2010). Oat 
bran containing a great amount of β-glucan and kidney beans with a lot of resistant 
starch and α-galactosides yield the highest amount of SCFA (McBurney et al. 
1988).  
 
The turnover rate of SCFA in blood is rapid: 29, 4 and 0.3 mmol/kg respectively 
for acetate, propionate and butyrate (Pouteau et al. 2007), effectively resulting in 
low but variable concentrations of SCFA in the blood (Table 1). 
  
H3C
O
OH H3C
OH
O
H3C OH
O
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 Table 1. Physiological concentrations of the three most common SCFA in fasting blood plasma, 
blood serum and blood; expressed in mean± standard deviation (SD) (µmol/l)  
 Acetate Propionate Butyrate  
Portal blood 258±98 88±68 29±19 Cummings et al. 1987 
Portal plasma 128.0±70.8 34.4±23.3 17.6±18.4 Peters et al. 1992 
Venous blood serum 245±9.4 13±0.5 2.1±0.1 Jakobsdottir et al. 2013 
Venous blood serum* 174 13 14 Zhao et al. 2007 
*No mean available 
 
The activity and composition of the gut microbiota is dependent, among others, on 
the diet and this affects the production and ratio of the SCFA (Rios-Covián et al. 
2016). Disruption in the microbiota composition and activity has been shown to be 
one of the important factors behind the increase in metabolic disorders (Leser & 
Mølbak 2009). Further studies have shown difference in microbiota between 
adults with T2D and non-diabetic adults (Larsen et al. 2010) and a recent study on 
mice has shown that the diet can affect the composition of the microbiota more 
than host genotype (Carmody 2015). 
 
Microbiota perturbation has been associating with T2D in a Chinese study, where 
subject with T2D displayed a lower level of butyrate producing bacteria (Qin et al. 
2012) and similarly in a European setting  (Karlsson et al. 2013). These changes 
have further been associated with obesity, insulin resistance and T2D (Musso et al. 
2010) and have generated an interest in altering the microbiota composition by 
dietary means as a possible route to health benefits. 
 
1.3  SCFA Metabolic Effects and Type 2 Diabetes  
Type 2 diabetes (T2D) is the most common type of diabetes and is also increasing 
on a global level (WHO 1999). It is preceded by a successive decrease in insulin 
sensitivity; which leads to metabolic dysregulation and finally T2D (Smushkin & 
Vella 2010). Insulin is the most important hormone for glucose regulation and 
decreased or disrupted insulin functionality will affect carbohydrate, fat and pro-
tein metabolism. In a healthy individual the insulin producing β-cells can adapt to 
changes in insulin level, but in the diseased state the β-cells are damaged and can 
no longer adapt adequately to elevated blood glucose, thus leading to hypergly-
caemia (Stumvoll et al. 2005). For diagnosis of T2D glucose level in the blood 
while fasting or 2 hours after an oral glucose tolerance test (OGTT) with an intake 
of 75 g glucose is measured. The limit for T2D is when at fasting state the glucose 
is ≥7.0 mmol 1-1  in plasma samples and ≥11.1 mmol 1-1 after OGTT (WHO 1999). 
 
The involvements of SCFA in numerous metabolic processes have generated a 
hypothesis of a possible mechanistic link to the metabolic syndrome and subse-
quent T2D.  The complete mechanism and action is not fully understood but the 
free fatty acid receptors 2 (FFAR2, or GP43) and 3 (FFAR3, or GP41) are sug-
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gested since SCFA are known to trigger and promote these receptors (Puddu et al. 
2014). FFAR2 has higher affinity to propionate than other SCFA whereas FFAR3 
is equally activated by acetate, propionate and butyrate. Both FFAR2 and FFAR3 
are expressed in adipose tissue, where the appetite supressing hormone leptin is 
present. Research has shown an increase in leptin secretion in tissues when the 
concentration of SCFA is high (Stoddart et al. 2008). These results correspond 
with the reduced obesity and insulin resistance reported in mice when treating with 
butyrate diet supplement (Gao et al. 2009). 
 
1.4  Method to Measure SCFA in Serum  
To gain an increased understanding of the kinetics and partitioning of SCFA in the 
different biocompartments it is important to be able to accurately measure circulat-
ing levels of SCFA. Moreover, circulating concentrations of SCFA will reflect a 
high or low consumption of DF in the diet (Zhao et al. 2005). Since in vivo   
measurements of SCFAs are a cumbersome task, various easier options have been 
developed. A number of methods have been used when measuring SCFA in faeces 
and blood e.g. enzymatic methods and a number of chromatography systems 
where gas chromatography (GC) is the most common (Zhao et al. 2005). 
 
 To be applicable to different study designs and sampling schemes, it is relevant to 
be able to measure SCFA in serum as well as plasma. The relation between plasma 
and serum concentrations is of importance when comparing studies made on dif-
ferent substances; to compare populations. An alternative reason to use serum 
instead of plasma is the possible easier injection of samples because of its inferior 
protein content. A reduction in sample volume is necessary to allow smaller sam-
ples to be analysed.  
 
1.5 Aim of the Thesis 
The aim of the thesis was to further develop and validate a rapid Gas Chromatog-
raphy-Mass Spectrometry (GC-MS) based method to accurately measure SCFA 
concentrations in serum from human subjects. Specific objectives included: i) to 
extend an existing protocol for SCFA analysis in 400 µl plasma to a smaller sam-
ple volume (200 µl) of serum; ii) to evaluate the agreement between methods us-
ing plasma or serum for determination of SCFA concentration in a small popula-
tion of individuals (n=30).  
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2 Materials and Method 
2.1 Samples 
The method was performed on fasting blood serum from three healthy volunteers. 
Samples were stored in -80°C and thawed in room temperature prior to analysis. 
EDTA-plasma and serum were obtained from 30 subjects’ participants in a pilot 
study to compare the SCFA concentration agreement in serum and EDTA-plasma. 
These samples were stored at -20°C prior to analysis. 
 
2.2 Chemicals  
Reagents: Acrylic acid (Sigma no. 127230), meta-phosphoric acid (Merck no. 
1.00546), propyl formate (Sigma-Aldrich no. W294306-1KG-K), sodium car-
bonate and sodium hydroxide (Merck no. 1.06469.1000).  
SCFA standards: Caproic acid (Fluka no. 21530), iso-valeric acid (Fluka no. 
59850), sodium acetate (Merck no. 6268), sodium butyrate (Ardrick no. 30.341.0), 
sodium iso-buryrate (Fluka no. 58360), sodium propionate (Sigma no. P 1880) and 
valeric acid (Fluka no. 94530). 
 
2.3 Preparation of Serum and Plasma Samples  
In brief, 100 μl of internal standard solution (150 µM acrylic acid, 1500 µM m-
phosphoric acid) was added to 200 μl serum or plasma. Samples were vortexed (5 
min; VWR VX-2500 Multi-Tube Vortexer) followed by centrifugation (30 min, 
20817 g; Eppendorf centrifuge 5417C, rotor: FA-45-30-11) and left for 30 min 
(4°C) to solidify the precipitate. In total, 100 μl of the clear supernatant was trans-
ferred into a new tube and 100 μl washed propyl formate was added. Samples 
were vortexed (5 min) followed by centrifugation (10 min, 20817 g) before trans-
ferring 50 µl of the organic layer into GC vials for analysis. Blank samples were 
prepared similarly with the exception that no serum or plasma was added.  
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 2.4 GC-MS analysis 
SCFA quantified employing a recently developed GC-MS method (Wu personal 
communication).  In brief, 2 µl sample was injected (splitless) into a straight glass 
liner, held at 200 °C. Helium (2 ml/min) was used as carrier gas in a ZB-FFAP 
column (30 m, 0.25 mm ID, no. 7HG-G009-11; Phenomenex, USA). The initial 
oven temperature of 55 °C was maintained for 4 min, then ramped to 130 °C at 50 
°C/min and held for 3.7 minutes and finally raised to 250 °C at 30 °C/min and held 
for 2 minutes. Electron ionization (70 eV and 250 °C) mode was used. All sam-
ples, standards and blanks were analysed randomly at the GC-MS system. Finni-
gan Trace GC Ultra Gas Chromatograph with a Finnigan Trace DSQ II mass de-
tector (Thermo Fisher Scientific, Waltham, MA, USA) were used. Integrations 
were performed automatically with Xcalibur 2.0.7(Thermo Fisher Scientific, Wal-
tham, MA, USA).  
 
The current method was developed and evaluated using 400 µl plasma in each 
sample. In this laboratory the volume were reduced to 200 µl; accuracy (by recov-
ery study) and precision (by coefficient of variation; CV) were estimated. A value 
below 15% is considered acceptable for most analytical methods (FDA 2011). In 
total eight quality plasma control samples with known concentration were tested, 
four with 200 µl and four with 400 µl (one sample could not be included due to 
waste of sample).  
 
Validation of the method was made for serum by calculating accuracy (by recov-
ery) and precision (by CV). The accuracy was estimated by adding standard solu-
tion with known concentration at three levels; low, medium and high according to 
Table 2. 
Table 2. Concentrations of spiking solution for validation of GC-MS method for quantification of 
SCFA in serum 
Spiking solution Concentration acetate (µM) Concentration SCFA C3-C6 (µM) 
Low 26.7 2.7 
Medium 53.3 5.3 
High 106.6 10.7 
 
A comparison between SCFA concentrations in serum and plasma was made by 
quantifying the concentration from the same individual (n=30). Bland-Altman 
plots present the result; the technique displays the difference of SCFA concentra-
tion between the two substances (Giavarina 2015). A t-test was also made to de-
termine the difference between serum and plasma concentration.  
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3 Result and Discussion 
3.1 Comparison Between 200 µl and 400 µl Plasma 
The result showed good recovery when using 200 µl-sample. The CV was be-
tween 2-25% for all analytes and all values except for propionate were below 15% 
of variation (Table 3). The deviant number is due to one sample with much lower 
concentration than the others. The variation when using 400 µl was between 0.6-
6% i.e. all values are below 15% of variation. When comparing the two different 
volumes the result were similar with regard to precision.  
 
The volume used is extremely crucial when quantifying. The small amount of 200 
µl makes it more difficult to perform the analysis, both analytically and the human 
factor has an impact on the result. The slightly higher variation of the 200 µl-
sample might be due to this. Alternative reason in difference of variation between 
the volumes might be the loss of one of the 400 µl-samples. Despite this a tripli-
cate should be enough for observing a credible trend. 
  
Table 3. Recovery of SCFA in serum. Within batch variation when using, 200µl and 400µl and re-
covery for 200µl.  
  
Sample Name ACE PRO ISO-BUT BUT ISO-VAL VAL CARP 
CV QC200 (%) 4.0 25.3 12.7 2.10 5.5 3.6 4.4 
CV QC400 (%) 2.1 5.2 5.7 0.6 0.9 0.8 5.9 
Recovery 200 (%) 100.4 77.8 98.5 94.7 88.5 106.1 98.3 
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3.2 Recovery Test 
The first test of recovery showed an uneven recovery between SCFA and in most 
cases the recovery rate was found too low (Table 4). During the test propyl for-
mate was added before the spiking solutions. This might have contributed to an 
increase in evaporation of SCFA due to their volatility. Additional reason was 
maybe too long time between sample preparation and injection of sample into GC. 
 Table 4. First recovery test with samples spiked at three different levels: high, medium and low 
 
During the second recovery test the spiking was added before propyl formate. This 
gives a protective surface, which captures and keeps the volatile SCFA in the tube. 
The time between sample preparation and injection of sample in to GC were re-
duced. As a result, the second test showed an even and high recovery between 80-
112% (Table 5).  The CV was small between spiking levels and quartets (Table 6). 
 Table 5. Second recovery test after spiking samples with high, medium and low amounts of SCFA 
Sample ACE PRO ISO-BUT BUT ISO-VAL VAL CARP 
RecoveryLow (%) 80.1 93.7 104.5 94.3 94.2 92.9 82.3 
RecoveryMedium (%) 92.0 111.8 101.1 97.4 96.4 93.6 80.8 
RecoveryHigh (%) 95.0 107.7 99.5 95.7 96.5 93.7 81.3 
Table 6. The coefficient of variance from the second recovery test 
Sample ACE PRO ISO-BUT BUT ISO-VAL VAL CARP 
CVLow (%) 4.1 1.9 0.5 0.1 0.6 1.0 2.4 
CVMedium(%) 4.5 1.2 1.3 1.4 1.8 1.9 2.0 
CVhigh (%) 3.0 1.6 1.0 1.1 0.3 2.2 2.4 
 
  
Sample ACE PRO ISO-BUT BUT ISO-VAL VAL CARP 
RecoveryLow (%) 13.9 87.0 104.8 85.6 73.4 70.9 71.7 
RecoveryMedium (%) 8.0 78.9 81.3 97.9 71.3 68.9 78.9 
RecoveryHigh (%) -44.7 73.1 77.0 125.0 68.0 68.6 85.0 
13 
 
3.3 Plasma vs Serum 
The concentration of acetate, propionate and butyrate in serum are within earlier 
measured concentration (Table 1). Iso-butyrate is also within range comparing 
with earlier measurements (Jakobsdottir et al. 2013; Zhao et al. 2007). The con-
centration of iso-valerate is in the lower segment of concentrations measured. The 
concentration of valerate is considerable lower in this study than previous (Jakob-
sdottir et al. 2013; Zhao et al. 2007).  Studies measuring caproate have not been 
found.  
Table 7. The concentration range and mean concentration for each SCFA in serum 
 ACE PRO ISO-BUT BUT ISO-VAL VAL CARP 
Range (μM) 86.0-313.3 19.4-28.5 2.6-4.7 9.2-29.1 11.2-44.4 0.2-0.4 1.4-9.7 
Mean (μM) 181.2±46.4 23.6±8.4 14.8±0.4 3.2±4.2 23.1±6.5 0.4±0.1 3.5±1.6 
 
Results from the comparison 
of analysis of SCFA in plasma 
and serum is presented in 
Bland-Altman plots (Figure 2-
8). The samples display a 
wide range of each SCFA 
concentration because of indi-
vidual DF intake. A good 
agreement was found between 
plasma and serum for butyrate 
(Figure 6). For propionate 
(Figure 8) and valerate (Fig-
ure 4) the concentrations did 
not differ that much between 
individuals, while we have a 
systematically low concentra-
tion of iso-butyrate (Figure 5) 
and iso-valerate (Figure 3), 
and higher concentration of 
acetate (Figure 2) and ca-
proate (Figure 7). 
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Figure 2. Bland-Altman plot of the difference between 
concentration of acetate determined by serum concentra-
tion minus plasma concentration on the Y-axis and aver-
age of the two substances on the X-axis. The dotted lines 
show the higher and lower limit of agreement. 
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Figure 3. Bland-Altman plot of the difference between 
concentration of iso-valerate determined by serum 
concentration minus plasma concentration on the Y-axis 
and average of the two substances on the X-axis. The 
dotted lines show the higher and lower limit of agree-
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Figure 4. Bland-Altman plot of the difference between 
concentration of valerate determined by serum concen-
tration minus plasma concentration on the Y-axis and 
average of the two substances on the X-axis. The dotted 
lines show the higher and lower limit of agreement. 
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Figure 5. Bland-Altman plot of the difference between 
concentration of iso-butyrate determined by serum concen-
tration minus plasma concentration on the Y-axis and aver-
age of the two substances on the X-axis. The dotted lines 
show the higher and lower limit of agreement. 
Figure 6. Bland-Altman plot of the difference between 
concentration of butyrate determined by serum concentra-
tion minus plasma concentration on the Y-axis and average 
of the two substances on the X-axis. The dotted lines show 
the higher and lower limit of agreement. 
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The t-test confirms the result and shows a significant difference between concen-
trations in serum and plasma for all SCFA except for butyrate (Table 8). 
Table 8. Result for the t-test between serum and plasma, a value <0.05 is considered as a significant 
difference  
 ACE PRO ISO-BUT BUT ISO-VAL VAL CARP 
P-value 7.7E-11 5.4E-09 2.1E-09 0.30 4.4E-12 6.7E-05 1,9E-10 
 
The samples used in this analysis were from a previous research project. The sam-
ples have earlier been thawed and then frozen again at least one time. Due to this, 
unwanted interactions between SCFA and protein may have occurred and proba-
bly some evaporation of SCFA. The changes might be due to the different chain 
lengths and branching of the SCFAs.  This might also be the reason for the some-
what lower concentrations of valerate and iso-valerate. Possible changes might 
also be due to the different deprotenization methods used when converting blood 
to serum or plasma. 
 
3.4 Further Studies 
During calculations of the concentration the blank value is subtracted, in this study 
the blank was constructed by the same means as samples, but with the exception 
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Figure 8. Bland-Altman plot of the difference between 
concentration of propionate determined by serum con-
centration minus plasma concentration on the Y-axis and 
average of the two substances on the X-axis. The dotted 
lines show the higher and lower limit of agreement. 
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Figure 7. Bland-Altman plot of the difference between 
concentration of caproic acid determined by serum con-
centration minus plasma concentration on the Y-axis and 
average of the two substances on the X-axis. The dotted 
lines show the higher and lower limit of agreement. 
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that no serum or plasma was added. A more accurate way of construction blanks 
would be by adding ex water to gain the same volume of each sample. To avoid 
unpredictable interactions it would be optimal to use fresh blood serum or plasma 
to minimize the possible risk for inadequate result and to be able to compare con-
centrations from different studies. To gain a sufficient result of the comparison 
more studies are needed.  
17 
 
4 Conclusion 
The developed method was able to analyse SCFA concentrations in human serum 
with good precision and accuracy. The reduced amount to 200 µl was not limiting.  
Further studies are though needed before a conclusion regarding agreement be-
tween SCFA concentrations in serum and plasma can be made.  
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